DOP2015000294A - Preparado farmacéutico - Google Patents
Preparado farmacéuticoInfo
- Publication number
- DOP2015000294A DOP2015000294A DO2015000294A DO2015000294A DOP2015000294A DO P2015000294 A DOP2015000294 A DO P2015000294A DO 2015000294 A DO2015000294 A DO 2015000294A DO 2015000294 A DO2015000294 A DO 2015000294A DO P2015000294 A DOP2015000294 A DO P2015000294A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- solution
- radionucclid
- issuer
- alfa
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dispersion Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Saccharide Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
UN MÉTODO PARA GENERAR UNA SOLUCIÓN PURIFICADA DE POR LO MENOS UN COMPLEJO DE RADIONÚCLIDO EMISOR ALFA. EL MÉTODO COMPRENDE PONER EN CONTACTO UNA SOLUCIÓN DEL COMPLEJO DE RADIONÚCLIDO EMISOR ALFA Y POR LO MENOS UN NÚCLIDO HIJO QUE TIENE POR LO MENOS UN LIGANTE SELECTIVO PARA LOS NÚCLIDOS HIJOS Y SUBSIGUIENTEMENTE SEPARAR LA SOLUCIÓN DEL LIGANTE SELECTIVO. TAMBIÉN, UN MÉTODO PARA SEPARAR POR LO MENOS UN RADIONÚCLIDO HIJO DE UNA SOLUCIÓN QUE COMPRENDE POR LO MENOS UN COMPLEJO DE RADIONÚCLIDO EMISOR ALFA. EL MÉTODO COMPRENDE PONER EN CONTACTO LA SOLUCIÓN QUE TIENE POR LO MENOS UN LIGANTE SELECTIVO PARA LOS NÚCLIDOS HIJOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2015000294A true DOP2015000294A (es) | 2016-03-15 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2015000294A DOP2015000294A (es) | 2013-06-05 | 2015-12-04 | Preparado farmacéutico |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (es) |
| EP (1) | EP3003401B1 (es) |
| JP (1) | JP6580559B2 (es) |
| KR (1) | KR102321763B1 (es) |
| CN (1) | CN105592863B (es) |
| AP (1) | AP2015008894A0 (es) |
| AU (1) | AU2014276885B2 (es) |
| BR (1) | BR112015030298A2 (es) |
| CA (1) | CA2914278C (es) |
| CL (1) | CL2015003554A1 (es) |
| CR (1) | CR20150642A (es) |
| CU (1) | CU24535B1 (es) |
| DK (1) | DK3003401T3 (es) |
| DO (1) | DOP2015000294A (es) |
| EA (1) | EA201501174A1 (es) |
| ES (1) | ES2782624T3 (es) |
| GB (1) | GB201310028D0 (es) |
| HR (1) | HRP20200456T1 (es) |
| IL (1) | IL242704B (es) |
| LT (1) | LT3003401T (es) |
| MA (1) | MA38650B1 (es) |
| MX (1) | MX366028B (es) |
| MY (1) | MY180717A (es) |
| NI (1) | NI201500173A (es) |
| PE (1) | PE20160215A1 (es) |
| PH (1) | PH12015502715A1 (es) |
| PL (1) | PL3003401T3 (es) |
| PT (1) | PT3003401T (es) |
| RS (1) | RS60091B1 (es) |
| SA (1) | SA515370233B1 (es) |
| SG (1) | SG11201509856RA (es) |
| SI (1) | SI3003401T1 (es) |
| TN (1) | TN2015000527A1 (es) |
| UA (1) | UA120352C2 (es) |
| WO (1) | WO2014195423A1 (es) |
| ZA (1) | ZA201600027B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| WO2010126979A1 (en) * | 2009-04-29 | 2010-11-04 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh active Active
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en active Application Filing
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
- 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en active Active
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko active IP Right Grant
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715A1/en unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2020
- 2020-03-19 HR HRP20200456TT patent/HRP20200456T1/hr unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
| CY1121750T1 (el) | Cot διαμορφωτες και μεθοδοι χρησης αυτων | |
| CY1118168T1 (el) | Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| BR112017010303A2 (pt) | anticorpos anti-cd47, métodos e usos | |
| CL2016001154A1 (es) | Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras. | |
| MX2021008755A (es) | Un anticuerpo anti-tau para usarse al tratar una tauopatia. | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| CR20150495A (es) | Procesos para la preparación de un agente inductor de la apoptosis | |
| CL2018000087A1 (es) | Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen | |
| CL2015002837A1 (es) | Compuestos de piridinilpirazoloquinolina. | |
| CL2015002358A1 (es) | Compuestos bicíclicos. | |
| DOP2015000294A (es) | Preparado farmacéutico | |
| MX2015015151A (es) | Metodo para producir 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos, donde dicho proceso usa reciclado. | |
| EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| JP2015101303A5 (es) | ||
| JP2015101487A5 (es) | ||
| BR112017007751A2 (pt) | Processo para a preparação de 5-bromo-1,2,3- triclorobenzeno. | |
| TR201303038A2 (tr) | Bir krem. | |
| TH1401002457B (th) | การลดบริบทสำหรับการลงรหัสเชิงเลขคณิตฐานสองแบบปรับตัวบริบทได้ | |
| CR20150630S (es) | Motocicleta | |
| EA201700030A1 (ru) | Липид, содержащий докозапентаеновую кислоту | |
| TH1501003975B (th) | โครงสร้างที่วางเท้าในยานพาหนะเเบบขับขี่บนอานนั่ง |